EUCTR2007-003159-36-SE进行中（未招募）不适用
An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients with major depressive disorder
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 615
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients.
- •2. 18 to 65 years of age.
- •3. Diagnosis of major depressive disorder, recurrent, as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) criteria (296.3) and confirmed by the semi-structured Mini International Neuropsychiatric Interview (MINI).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than 24 (<24) at Visit 1 (Day –7) or Visit 2 (Day –1).
- •- 17-item HAM-D total score of less than 18 (<18) at Visit 1 (Day –7) or Visit 2 (Day –1)
研究者
相似试验
进行中（未招募）
1 期
An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients with major depressive disorderEUCTR2007-003159-36-FRsanofi-aventis recherche & développement675
进行中（未招募）
不适用
An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients with major depressive disorderEUCTR2007-003159-36-FIsanofi-aventis recherche & développement615
进行中（未招募）
不适用
An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy, safety and tolerability of a fixed dose of SR58611A (350 mg q12) in outpatients with Generalized Anxiety Disorder. - NAEUCTR2005-003181-41-SEsanofi-aventis recherche & développement360
进行中（未招募）
不适用
An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy, safety and tolerability of a fixed dose of SR58611A (350 mg q12) in outpatients with Generalized Anxiety Disorder. - NAGeneralized Anxiety Disorder (GAD)MedDRA version: 8.0Level: LLTClassification code 10018105EUCTR2005-003181-41-EEsanofi-aventis recherche & développement360
进行中（未招募）
不适用
An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy, safety and tolerability of a fixed dose of SR58611A (350 mg q12) in outpatients with Generalized Anxiety Disorder. - NAGeneralized Anxiety Disorder (GAD)MedDRA version: 8.0Level: LLTClassification code 10018105EUCTR2005-003181-41-ATSanofi-Synthelabo Recherche360